Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major
Alzamend Neuro seals $500,000 Series A Convertible Preferred Stock deal with an investor. Plans to raise up to $25 million for clinical trials and working capital.
Alzemend Neuro made waves Tuesday when the company announced its decision to terminate its "at-the-market" equity offering program. Shares were down nearly 12% at last check.
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major